A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda) in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1b, Open-Label, Dose-Escalating Trial of Tivozanib (AV-951) in Combination With Capecitabine (Xeloda) in Subjects With Advanced Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2014

At a glance

  • Drugs Tivozanib (Primary) ; Capecitabine
  • Indications Advanced breast cancer; Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Jun 2012 Additional lead trial investigator (Shefali Agarwal) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top